ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.17
+3.70%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 164.92x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.29x
- Price / sales
- 110.50x
- Price / cash flow
- -14.63x
Enterprise value
- Enterprise value
- $816.7M
- EV / sales
- 99.36x
- EV / EBITDA
- -10.87x
- EV / EBIT
- -9.46x
- Market cap
- $908.2M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026